The existing data report that in human breast cancer cells, iPA-induced effects can be mediated by the inhibition of the Akt/NFκB cell survival pathway [11] and more recently it has been reported that iPA, phosphorylated by adenosine kinase (ADK) into 5′-iPA-monophosphate (iPAMP), is able to inhibit angiogenesis in vitro and in vivo, triggering the AMP-activated protein kinase (AMPK) [12]. The gene discussed is ADK; the disease is breast cancer.